Edition:
India

Elanco Animal Health Inc (ELAN.N)

ELAN.N on New York Stock Exchange

32.29USD
1:30am IST
Change (% chg)

$-0.45 (-1.37%)
Prev Close
$32.74
Open
$32.42
Day's High
$32.72
Day's Low
$31.71
Volume
571,780
Avg. Vol
1,944,657
52-wk High
$36.50
52-wk Low
$28.50

Summary

Name Age Since Current Position

R. David Hoover

Chairman of the Board

Jeffrey Simmons

51 President, Chief Executive Officer, Director

Todd Young

46 2018 Chief Financial Officer

Michael-Bryant Hicks

43 Executive Vice President, General Counsel, Secretary

Ramiro Cabral

47 Executive Vice President - Elanco International and Global Customer Value

David Kinard

51 Executive Vice President - Human Resources, Corporate Affair

Sarena Lin

47 Executive Vice President - Elanco USA, Global Strategy

Aaron Schacht

51 Executive Vice President - Innovation, Regulatory, Business Development

David Urbanek

52 Executive Vice President - Manufacturing, Quality

John Bilbrey

62 2019 Director

Art Garcia

57 2019 Director

Deborah Kochevar

61 2019 Director

Kirk McDonald

2019 Director

Denise Scots-Knight

1 2019 Director

Kapila Anand

64 Independent Director

Michael Harrington

55 Independent Director

Lawrence Kurzius

60 Independent Director

Carl McMillian

52 Independent Director

David Ricks

51 Independent Director

Aarti Shah

54 Independent Director

Joshua Smiley

49 Independent Director

Biographies

Name Description

R. David Hoover

Mr. R. David Hoover is the the chairman of our board upon completion of this offering. Mr. Hoover has been retired since 2013. Prior to that, Mr. Hoover served in various roles at Ball Corporation, including Chairman from 2002 to 2013, Chief Executive Officer from 2010 to 2011, President and Chief Executive Officer from 2001 to 2010, Chief Operating Officer from 2000 to 2001 and Chief Financial Officer from 1998 to 2000. Mr. Hoover currently serves on the boards of directors of Ball Corporation and Edgewell Personal Care Company. Mr. Hoover's experience described above, including his extensive management experience as Chief Executive Officer and Chief Financial Officer at Ball Corporation and corporate governance experience through his service on other public boards, including nine years he previously served as a director for Lilly, provides him with the qualifications and skills to serve as a director on our board.

Jeffrey Simmons

Mr. Jeffrey N. Simmons is the President, Chief Executive Officer and Director of the Company. Mr. Simmons has served as the President of the Elanco Animal Health division of Lilly and Senior Vice President of Lilly since 2008. Prior to 2008, Mr. Simmons held various leadership roles for Elanco, including District Sales Manager, International Marketing Manager, Country Director for Brazil, Area Director for Western Europe and Executive Director for U.S. and Global Research & Development.

Todd Young

Mr. Todd S. Young is Chief Financial Officer of the Company. Mr. Young joins Elanco from ACADIA Pharmaceuticals, a biopharmaceutical company, where he served as Executive Vice President and Chief Financial Officer since August 2016. From 2015 to 2016, Mr. Young served as Senior Vice President and Treasurer for Baxalta Incorporated, a global biopharmaceutical company. Prior to Baxalta, Mr. Young worked for over 14 years at Baxter International, Inc., a global diversified healthcare company, holding multiple leadership roles, including Corporate Vice President and Treasurer from 2013 to 2015.

Michael-Bryant Hicks

Mr. Michael-Bryant Hicks is an Executive Vice President, General Counsel and Corporate Secretary upon completion of this offering. Mr. Hicks has served as General Counsel of the Elanco Animal Health division of Lilly since May 2018. Prior to joining Elanco, Mr. Hicks served in various legal roles, including General Counsel at Mallinckrodt Public Liability Company from 2016 to 2018, Senior Vice President, General Counsel and Corporate Strategy at The Providence Service Corporation from 2014 to 2016 and as Assistant General Counsel at DaVita Inc. from 2011 to 2013.

Ramiro Cabral

Mr. Ramiro M. Cabral is the Executive Vice President, Elanco International and Global Customer Value of the Company. Mr. Cabral has served as Vice President and Chief Marketing Officer of the Elanco Animal Health division of Lilly since 2017. Mr. Cabral joined Lilly in 2005 and has held various leadership positions for Elanco, including Vice President and Head of Operations for Elanco EMEA from 2013 to 2017 and Senior Director, U.S. Beef Business Unit from 2011 to 2013.

David Kinard

Mr. David S. Kinard is an Executive Vice President, Human Resources and Corporate Affairs upon completion of this offering. Mr. Kinard has served as Vice President of Human Resources and Global Learning and Development for the Elanco Animal Health division of Lilly since May 2018. Prior to May 2018, Mr. Kinard served in various leadership roles for Lilly, including Vice President of Human Resources for a variety of Lilly businesses, including Lilly International in 2017, Bio-Medicines and Emerging Markets from 2015 to 2017 and Lilly Diabetes and Global Employee Relations/HR Operations from 2011 to 2015.

Sarena Lin

Ms. Sarena S. Lin is the Executive Vice President, Elanco USA and Global Strategy of the Company. Ms. Lin has served as Senior Vice President of North American Operations and Strategy at the Elanco Animal Health division of Lilly since January 2018. Prior to joining Lilly, Ms. Lin served as President of Cargill Feed & Nutrition from 2014 to 2017. Prior to 2014, Ms. Lin served as Global Head of Strategy and Business Development for Cargill from 2011 to 2014. Ms. Lin served on the board of directors for the animal health and dental distributor, Patterson Companies, from 2014 to 2018.

Aaron Schacht

Mr. Aaron L. Schacht is an Executive Vice President, Innovation, Regulatory and Business Development of the Company. Mr. Schacht has served as the Vice President of global research and development of the Elanco Animal Health division of Lilly since 2015. Prior to 2015, Mr. Schacht served in various leadership roles for Lilly, including Global Brand Development Leader of Pain in Lilly BioMedicines in 2014, Senior Advisor of Strategy & Business Development for Lilly BioMedicines from 2012 to 2014 and Executive Director of Global External R&D at Lilly from 2008 to 2012.

David Urbanek

Mr. David A. Urbanek is the Executive Vice President, Manufacturing and Quality of the Company. Mr. Urbanek has served as Vice President of Manufacturing at the Elanco Animal Health division of Lilly since November 2017. Prior to that, Mr. Urbanek served in various leadership roles for Lilly's Manufacturing division, including Senior Director of Emerging Markets Manufacturing from 2013 to 2017, Senior Director of Global Diabetes Manufacturing from 2011 to 2013 and Senior Director of External Drug Products Operations from 2009 to 2011.

John Bilbrey

Mr. John P. Bilbrey is Director of the company. He is the former chairman and CEO of The Hershey Company from 2011 to 2017. Prior to holding the top spot with Hershey, he held various roles of increasing importance, including chief operating officer and senior vice president of Hershey International. Before joining Hershey in 2003, he was president, CEO and executive vice president of Retail Sales of Danone Water of North America, after beginning his career with Procter & Gamble (P&G). In addition to his role as Non-Executive Chairman of The Hershey Company, he also served on the Board of Directors of McCormick & Company, Incorporated and Colgate-Palmolive Company. Bilbrey is also the owner and operator of Bilbrey Farms and Ranch, a commercial cattle operation in Kansas. His unique combination of livestock production, food industry and consumer insights experience will be a strong asset for Elanco. `

Art Garcia

Mr. Art A. Garcia is Director of the company. Garcia, a certified public accountant, began his career with Coopers & Lybrand before joining Ryder, the $8 billion Miami-based provider of fleet management, supply chain management and logistic solutions. While at Ryder, Garcia held several positions of increasing responsibility, including group director accounting services, as well as senior vice president and corporate controller before his appointment as CFO in 2010. In addition to his responsibilities as CFO, Garcia oversaw corporate strategy and development, and led the reengineering of the company's finance function to drive increased efficiencies. Garcia also was a key member of the Ryder executive team that established a new business model and implemented strategies to revitalize growth and improve profitability.

Deborah Kochevar

Dr. Deborah Turner Kochevar is Director of the company. she is provost and senior vice president ad interim at Tufts University. She is the former dean and Henry and Lois Foster professor at Cummings School of Veterinary Medicine at Tufts. Prior to Tufts, Dr. Kochevar was a member of the faculty at Texas A&M University following the completion of a National Institutes of Health (NIH) National Research Service Award Fellowship. She also served as the president and chair of the board of directors of the Association of American Veterinary Medical Colleges. Dr. Kochevar holds an undergraduate degree from Rice University, a doctorate of veterinary medicine from Texas A&M University and a doctorate from the University of Texas Southwestern Graduate School of Biomedical Sciences. She has also served on the board of Charles River Laboratories, Inc. since 2008. Her deep animal health expertise and One Health approach will add to Elanco's focus on delivering best-in-class innovation across the portfolio.

Kirk McDonald

Mr. Kirk McDonald is Director of the company, he serves as the chief marketing officer of Xandr, AT&T's Advertising company. Xandr was created in the fall of 2017 to create a better advertising experience for consumers and brands. Xandr is building an innovative advertising platform focused on transparency and brand-safe placement in premium content. McDonald brings more than 25 years of experience with some of the world's leading brands and software technology providers to Elanco, including having served as president of Digital at Time Inc. and chief advertising officer for the Fortune|Money Group. His proficiency driving digital transformation, marketing capability and know-how in using cutting-edge technology to connect with today's customers will bring a valuable perspective to Elanco.

Denise Scots-Knight

Dr. Denise Scots-Knight is Director of the company. currently serves as CEO and co-founder of Mereo BioPharma, a specialty biopharmaceutical company that acquires, develops and commercializes therapeutics for the treatment of rare diseases. Dr. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry in both research and development management and as a venture capitalist. Prior to co-founding Mereo BioPharma, Scots-Knight ran Phase4 Partners, a venture capital business that invested globally in biotechnology companies, having previously led the management buy-out of the business from Nomura. She began her career in R&D management at Amersham and Fisons, and as a senior executive at Scientific Generics before joining Rothchild Asset Management as an investment manager. Her extensive previous board leadership, history leading an innovation and growth-oriented company, and expertise building innovation models and partnerships will bring value to Elanco.

Kapila Anand

Ms. Kapila K. Anand is an Independent director of the Company. Ms. Anand has served as a Senior Advisor to KPMG LLP since 2016. Prior to that, Ms. Anand served in various leadership roles as a partner at KPMG LLP, including Industry Segment Leader — Travel, Leisure and Hospitality from 2011 to 2017, Partner in Charge — Public Policy Business Initiatives from 2009 to 2013, KPMG LLP Board member from 2005 to 2010, Advisory Leader — Private Equity, Real Estate and Hospitality from 2002 to 2009 and Audit Partner — Real Estate and Hospitality from 1989 to 2002. Ms. Anand currently serves on the boards of directors of Extended Stay America, Inc. and Omega Healthcare Investors, Inc.

Michael Harrington

Mr. Michael J. Harrington is an Independent Director of the Company. Mr. Harrington has served as the Senior Vice President and General Counsel for Lilly since January 2013. Prior to 2013, Mr. Harrington served in various legal roles for Lilly, including Vice President and Deputy General Counsel of Global Pharmaceutical Operations from 2010 to 2012 and Vice President and General Counsel, Corporate from 2004 to 2010. Mr. Harrington's experience described above, including his knowledge of our company and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on our board.

Lawrence Kurzius

Mr. Lawrence Erik. Kurzius is an Independent Director of the Company. Mr. Kurzius has served in various leadership roles at McCormick & Company, including director since 2015 and Chairman of the Board of Directors since 2017, Chief Executive Officer since 2016, President since 2015, Chief Operating Officer from 2015 to 2016, Chief Administrative Officer from 2013 to 2015, President, International Businesses from 2008 to 2013, President, Europe, Middle East and Africa from 2007 to 2008 and President, U.S. Consumer Foods from 2005 to 2006.

Carl McMillian

Mr. Carl L. McMillian is an Independent Director of the Company. Mr. McMillian has served as Vice President of Toxicology, Drug Disposition, PKPD, Veterinary Resources & Experimental Medicine of Lilly since 2012. Prior to that, Mr. McMillian served in various leadership roles for Lilly, including Senior Director, Drug Disposition from 2008 to 2012 and Director, Drug Disposition from 2002 to 2008.

David Ricks

Mr. David A. Ricks is an Independent Director of the Company. Mr. Ricks has served as the Chief Executive Officer and President of Lilly since January 2017; Mr. Ricks joined the board of Lilly in January 2017 and became Chairman in June 2017. Prior to that, Mr. Ricks served in various leadership roles for Lilly, including President of Lilly Bio-Medicines from 2012 to 2016 and President of Lilly USA from 2009 to 2012.

Aarti Shah

Ms. Aarti S. Shah, Ph.D., is an Independent Director of the Company. Ms. Shah has served as Senior Vice President and Chief Information Officer of Lilly since July 2016. Prior to that, Ms. Shah served in various leadership roles for Lilly, including Global Brand Leader of the Autoimmune Division of Lilly Bio-Medicines from 2013 to 2016 and Vice President of Biometrics & Advanced Analysis from 2009 to 2013. Ms. Shah's experience described above, including her knowledge of our company and the animal health industry and her business and management experience, provides her with the qualifications and skills to serve as a director on our board.

Joshua Smiley

Mr. Joshua L. Smiley is an Independent Director of the Company. Mr. Smiley has served as Senior Vice President and Chief Financial Officer of Lilly since January 2018. Prior to January 2018, Mr. Smiley held a variety of leadership positions at Lilly, including Senior Vice President and Treasurer in 2017 and Senior Vice President of Finance, Corporate Controller and Chief Financial Officer of Lilly Research from 2011 to 2015. Mr. Smiley's experience described above, including his knowledge of our company and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on our board.